Lisata Therapeutics Inc. Total Liabilities
Lisata Therapeutics Inc. total liabilities. Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has total liabilities worth $3.04 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LSTA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lisata Therapeutics Inc. (1990–2025)
Total liabilities of Lisata Therapeutics Inc. from 1990 to 2025. This chart illustrates how Lisata Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore LSTA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Lisata Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Lisata Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daewoo SBI SPAC 1
KQ:215480
|
Korea | ₩7.64 Billion |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
USA | $24.02 Million |
|
Regenbogen AG
F:RGB
|
Germany | €24.18 Million |
|
Energisme
PA:ALNRG
|
France | €13.29 Million |
|
Minbos Resources Ltd
AU:MNB
|
Australia | AU$2.11 Million |
|
Ecocab Co. Ltd
KQ:128540
|
Korea | ₩58.36 Billion |
|
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
|
India | Rs5.75 Billion |
|
Prodigy Gold NL
AU:PRX
|
Australia | AU$2.15 Million |
Liability Composition Analysis (1990–2025)
This chart breaks down Lisata Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LSTA total assets.
Liquidity & Leverage Metrics
Lisata Therapeutics Inc. Total Liabilities Ratios Explained
Lisata Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lisata Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lisata Therapeutics Inc. (1990–2025)
The table below shows the annual total liabilities of Lisata Therapeutics Inc. from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.14 Million | -44.71% |
| 2024-12-31 | $5.68 Million | -16.40% |
| 2023-12-31 | $6.80 Million | +1.34% |
| 2022-12-31 | $6.71 Million | +33.99% |
| 2021-12-31 | $5.01 Million | +33.19% |
| 2020-12-31 | $3.76 Million | -43.03% |
| 2019-12-31 | $6.60 Million | -7.38% |
| 2018-12-31 | $7.13 Million | -45.96% |
| 2017-12-31 | $13.19 Million | -72.40% |
| 2016-12-31 | $47.77 Million | +40.81% |
| 2015-12-31 | $33.92 Million | -50.26% |
| 2014-12-31 | $68.20 Million | +145.42% |
| 2013-12-31 | $27.79 Million | +28.74% |
| 2012-12-31 | $21.59 Million | -71.29% |
| 2011-12-31 | $75.20 Million | +33.00% |
| 2010-12-31 | $56.54 Million | +21.72% |
| 2009-12-31 | $46.45 Million | +4732.58% |
| 2008-12-31 | $961.14K | +109.42% |
| 2007-12-31 | $458.95K | -49.17% |
| 2006-12-31 | $902.87K | -63.30% |
| 2005-12-31 | $2.46 Million | +21.12% |
| 2004-12-31 | $2.03 Million | +11.95% |
| 2003-12-31 | $1.81 Million | -9.60% |
| 2002-12-31 | $2.01 Million | +37.23% |
| 2001-12-31 | $1.46 Million | -1.64% |
| 2000-12-31 | $1.49 Million | +19.12% |
| 1999-12-31 | $1.25 Million | +2.86% |
| 1998-12-31 | $1.21 Million | +82.05% |
| 1996-12-31 | $666.62K | +46.41% |
| 1995-12-31 | $455.31K | -96.41% |
| 1994-12-31 | $12.70 Million | +64.94% |
| 1993-12-31 | $7.70 Million | +92.50% |
| 1990-12-31 | $4.00 Million | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more